Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.
暂无分享,去创建一个
[1] H. Iwase,et al. Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer , 2008, Breast Cancer Research and Treatment.
[2] Michael Höckel,et al. Detection and characterization of tumor hypoxia using pO2 histography. , 2007, Antioxidants & redox signaling.
[3] Michael Höckel,et al. Impact of Hemoglobin Levels on Tumor Oxygenation: the Higher, the Better? , 2006, Strahlentherapie und Onkologie.
[4] Peter Vaupel,et al. The role of hypoxia-induced factors in tumor progression. , 2004, The oncologist.
[5] O. Alqawi,et al. Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells , 2007, Free radical research.
[6] G. Semenza,et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.
[7] C. Rübe,et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial , 2003, The Lancet.
[8] L. Orci,et al. Proteolytic balance and capillary morphogenesis in vitro. , 1992, EXS.
[9] Remo Guidieri. Res , 1995, RES: Anthropology and Aesthetics.
[10] Adrian L Harris,et al. Angiogenesis in endocrine tumors. , 2003, Endocrine reviews.
[11] E. Rofstad,et al. Fluctuating and Diffusion-Limited Hypoxia in Hypoxia-Induced Metastasis , 2007, Clinical Cancer Research.
[12] D. McDonald,et al. Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.
[13] P. Vaupel,et al. Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.
[14] L. Orci,et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. , 1991, Biochemical and biophysical research communications.
[15] G. Semenza,et al. Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression , 2000, Critical reviews in biochemistry and molecular biology.
[16] P. Vaupel. Abnormal Microvasculature and Defective Microcirculatory Function in Solid Tumors , 2006 .
[17] P. Okunieff,et al. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.
[18] J. Nortier,et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Giaccia,et al. Hypoxic Stress Proteins: Survival of the Fittest. , 1996, Seminars in radiation oncology.
[20] G. Friedell. ANÆMIA IN CANCER , 1965 .
[21] G. Semenza,et al. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.
[22] J. M. Arbeit,et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. , 2000, Cancer research.
[23] S. Påhlman,et al. Effect of hypoxia on the tumor phenotype: the neuroblastoma and breast cancer models. , 2006, Advances in experimental medicine and biology.
[24] G. Semenza,et al. Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. , 2001, The Journal of clinical investigation.
[25] R. Hill,et al. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. , 2001, Cancer research.
[26] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[27] P. Vaupel,et al. Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia , 2005, Oncology Research and Treatment.
[28] Dietmar W. Siemann,et al. Vascular targeted therapies in oncology , 2008, Cell and Tissue Research.
[29] H. Feldmann,et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. , 2000, International Journal of Radiation Oncology, Biology, Physics.
[30] R. Czekay,et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins , 2003, The Journal of cell biology.
[31] Michael Höckel,et al. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. , 2003, Cancer research.
[32] J. Baselga,et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Richard P. Hill,et al. Acute Hypoxia Enhances Spontaneous Lymph Node Metastasis in an Orthotopic Murine Model of Human Cervical Carcinoma , 2004, Cancer Research.
[34] P Vaupel,et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.
[35] P. Vaupel,et al. Erythropoiesis-Stimulating Agents: Favorable Safety Profile When Used as Indicated , 2008, Strahlentherapie und Onkologie.
[36] P. Vaupel,et al. Hypoxia and anemia: effects on tumor biology and treatment resistance. , 2005, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.
[37] E. Fredlund,et al. Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors. , 2005, Seminars in cell & developmental biology.
[38] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[39] A. Osterborg. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? , 1998, Medical oncology.